Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Avi Kapoor

Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades'

Side,View,Of,Concentrated,Crypto,Trader,Sitting,In,Front,Of

On CNBC's “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he is staying long on AbbVie Inc. (NYSE:ABBV).

Supporting his view, Guggenheim analyst Vamil Divan maintained an AbbVie Buy rating on Oct. 20, raising the price target from $227 to $242.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.